Arkin ramping up investments with $140M fund

Israeli VC to invest in companies developing cancer, rare disease, RNA and gene therapies

Arkin Holdings closed its second biopharma fund Monday at $140 million, more than double its debut fund, which launched with $60 million in 2016 and was fully committed at the end

Read the full 315 word article

How to gain access

Continue reading with a
two-week free trial.